Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D-flaxane ER
- Development stage
- Unknown
- Lead developer
- Vanprom Lifesciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
D-flaxane ER is an extended-release formulation of desvenlafaxine, a small molecule serotonin-norepinephrine reuptake inhibitor (SNRI) marketed by Vanprom Lifesciences in India. It is available in 50 mg and 100 mg tablet strengths and is indicated for the treatment of major depressive disorder (depression) and anxiety. Desvenlafaxine works by inhibiting the serotonin transporter (SERT) and norepinephrine transporter (NET), thereby increasing the levels of these neurotransmitters in the brain.
- Brand names
- D-FLAXANE-ER-50/100D-Flaxane ER
- Other names
- desvenlafaxinedesvenlafaxine extended-release
02
Targets
NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on D-flaxane ER.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on D-flaxane ER.